ICU Medical FY Conference Summary Company Overview - **Company Name**: ICU Medical - **Ticker**: NasdaqGS:ICUI - **Market Capitalization**: $2.1 billion - **Focus**: Primarily on infusion therapy, which is described as the "plumbing of the hospital" [2][3] - **Revenue Segments**: - **Consumables**: Largest segment, includes items that connect pumps to patients - **Systems**: Includes various types of infusion pumps - **Vital Care**: Ancillary critical care products [3][4] Financial Highlights - **Current Share Price**: Approximately $150 per share - **Equity Value**: About $3.8 billion - **Net Debt**: Just under $1 billion - **Leverage Ratio**: Approximately 2.4 times [6] - **Revenue Distribution**: 2/3 of revenue from North America, primarily the U.S. and Canada [5] - **Product Pricing**: 87%-88% of products are single-use disposables, typically priced under $12 [5] Industry Insights - **IV Therapy Market**: - 90% of hospital patients receive some form of IV therapy [7] - Market characterized by high regulatory barriers, which protect against low-cost competitors [8] - Consolidated industry with few major players [7][8] Growth and Innovation - **Historical Growth**: - Consumables grew 6% in the last year, while systems grew 5% [13] - Previous years showed similar growth rates [13] - **Innovation Strategy**: Focus on incremental innovations rather than major breakthroughs, particularly in consumables [14][15] - **New Product Cycles**: Anticipated launches of new products and software solutions [29] Challenges and Opportunities - **Operational Challenges**: Issues in production affecting the vascular access segment, which is lagging in growth [39] - **Pricing Pressures**: Absorbed inflation costs from 2022 to 2024, with a focus on regaining pricing power [17] - **Regulatory Environment**: Ongoing changes that could impact product development and market entry [25] Strategic Priorities - **Core Revenue Growth**: Aim to maintain consistent growth in consumables and systems [14] - **Innovation Roadmap**: Focus on small, incremental improvements to existing products [14] - **Financial Goals**: Targeting gross margins to improve from 41% to 43% by the end of the next year [27][28] Market Positioning - **Competitive Advantage**: Strong brand recognition and extensive product history in consumables [13] - **Integration of Acquisitions**: Successful integration of Smiths Medical and other acquisitions to enhance product offerings [11][12] Future Outlook - **Market Trends**: Growth in biologics and home infusion markets, which are expanding faster than acute care markets [16] - **Financial Improvement**: Expected improvements in cash flow and earnings per share as operational challenges are addressed [30] Conclusion - **Investment Rationale**: ICU Medical is positioned at an inflection point with new product cycles, improving financials, and a strong recurring revenue base, making it an attractive investment opportunity [30]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][18] - Adjusted gross margin for Q4 was 40.5%, in line with previous guidance, with adjusted EBITDA decreasing by 7% from $106 million last year [16][18] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth at 7% reported and 6% organic [7][8] - IV systems business grew 3% reported and 1% organic, with LVPs showing low double-digit growth for the year [8][9] - Vital Care decreased 6% organically and 35% reported due to the deconsolidation of IV Solutions, with expectations for flat to slightly down revenue in the near term [10][11] Market Data and Key Metrics Changes - The demand environment remained attractive across geographies, with a notable flu spike in the U.S. towards year-end [6] - The capital environment was stable, with investments being made as needed [7] - Currency fluctuations, particularly the weaker U.S. dollar, positively impacted revenues in selling geographies [7] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation [4][32] - Future growth is expected to be driven by volume increases in core infusion lines and niche categories like oncology [20][21] - The company is working on modernizing its IV Solutions business through a joint venture with Otsuka [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the capital environment and ongoing demand for their products [6][7] - The company anticipates improved free cash flow in 2026, driven by higher earnings and reduced spending on restructuring and integration [26] - Management acknowledged challenges from tariffs and interest rates but believes they can overcome these hurdles [29][34] Other Important Information - The company ended 2025 with $1.3 billion in debt and $308 million in cash, having paid down $303 million in principal during the year [20][27] - Adjusted operating expenses were 25% of revenue, lower than previous guidance, due to cost controls [17] - The company expects to reach a targeted leverage ratio of 2x by early 2027, prioritizing debt paydown with free cash flow [27] Q&A Session Summary Question: Can you discuss the current capital environment and customer decision-making? - Management indicated that the capital environment has been stable, with deals getting done and no significant changes from historical behavior [39] Question: What is the expected impact of new product launches on sales? - Management confirmed that there has been no slowdown in customer interest regarding future product roadmaps, and they are optimistic about upcoming clearances [43][45] Question: How is the company addressing tariff impacts? - Management noted that while there are still challenges related to tariffs, they have implemented structural changes to mitigate these impacts [55] Question: What is the outlook for the Syringe Pumps market? - Management clarified that the Syringe Pumps market is smaller than LVPs but emphasized the importance of having an integrated view for customers [60] Question: What are the margins for the Critical Care business? - Management indicated that most of the Vital Care business likely operates below corporate gross margins, complicating potential divestiture discussions [64]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][17] - Adjusted gross margin for Q4 was 40.5%, with adjusted EBITDA decreasing by 7% from $106 million last year [15][17] - Free cash flow for Q4 was $44 million, contributing to a total of $100 million for the year, slightly better than guidance [18][25] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth at 7% reported and 6% organic [6][7] - IV systems business grew 3% reported and 1% organic, with the best quarter in pumps despite some installations being pulled into Q3 [7][8] - Vital Care decreased 6% organically and 35% reported due to deconsolidation, remaining flat for the year [9] Market Data and Key Metrics Changes - The demand environment in Q4 was strong across most geographies, with a notable flu spike in the U.S. towards year-end [5] - The capital environment remained stable, with investments being executed as planned [6] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation to improve performance in vascular access [6][31] - The strategy includes modernizing the IV solutions business through a joint venture with Otsuka and enhancing product offerings with FDA-cleared devices [30][32] - Long-term goals include achieving mid-single-digit growth in consumables and infusion systems, while Vital Care is expected to remain flat to slightly down [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational improvements and expected benefits from completed integration projects, leading to better cash flow and margins [27][81] - The company anticipates challenges from tariffs and interest rates but believes it can overcome these hurdles to achieve original targets [28][33] Other Important Information - The company has made significant progress in integrating manufacturing sites and IT systems, which is expected to yield operational synergies [11][12] - The company plans to prioritize debt repayment with free cash flow generated in 2026, targeting a long-term leverage ratio of 2 times [26] Q&A Session Summary Question: Current environment for systems and customer decision-making - Management indicated that the capital environment is stable, with deals being executed as expected [39] Question: Impact of new product cycles and competitive landscape - Management noted that while competitive challenges exist, they are starting from a stronger position and expect to grow through existing headwinds [76] Question: Underlying volume trends in consumables - Management confirmed that underlying demand remains positive, despite some seasonal fluctuations [54] Question: Tariff mitigation efforts - Management stated that structural changes have been made to mitigate tariff impacts, with some benefits already seen in Q4 [57] Question: Potential sale of the critical care business - Management acknowledged the complexities involved in assessing the critical care business due to its integration with other operations [66]

Financial Data and Key Metrics Changes - Revenue for Q2 was $544 million, reflecting a 2% organic growth but a reported decline of 6% due to the impact of the joint venture [5][6] - Adjusted EBITDA was $100 million, with EPS at $2.1, and gross margins improved due to the joint venture [6][14] - Adjusted gross margin for Q2 was 40%, showing a three percentage point expansion year-over-year and sequentially [14][15] - Free cash flow was a net outflow of $8 million, influenced by higher tax payments and tariff payments [17][18] Business Line Data and Key Metrics Changes - Consumables business grew 4% organically and 3% reported, achieving record sales levels [7][8] - IV Systems business grew 2% organically and reported, driven by double-digit growth in LVP [9][10] - Vital Care segment reported a decline of 434% due to the deconsolidation of IV Solutions revenues [12][13] Market Data and Key Metrics Changes - The demand and utilization environment in Q2 remained attractive across most geographies, although growth rates were not as high as the previous year [6][24] - The capital environment is stable, with customers proceeding with necessary investments [6] Company Strategy and Development Direction - The company aims to build a comprehensive infusion therapy company, focusing on innovation and optimizing its portfolio [5][26] - The strategy includes enhancing patient safety and workflow efficiencies through new product developments and regulatory approvals [8][11] - The company is focused on mitigating tariff impacts and optimizing its manufacturing network to improve profitability [30][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by tariffs and their impact on profitability, emphasizing the need for cost controls and price increases [20][30] - The outlook for Q3 and Q4 is positive, with expectations for sequential growth in consumables and IV systems [24][51] - The company is cautious about the evolving tariff landscape and its potential long-term implications [58] Other Important Information - The company has made significant progress in integrating its IT systems and consolidating its manufacturing network [15][31] - The joint venture is expected to continue benefiting the balance sheet and income statement [31] Q&A Session Summary Question: What assumptions have been made regarding tariffs, particularly for China? - The current guidance assumes tariffs at existing rates, with some benefits from pauses in tariff increases [38] Question: Is there anything outside of tariffs impacting the EBITDA outlook? - The primary impact on the EBITDA outlook is from tariffs, with no other significant factors affecting the guidance [39] Question: What is the demand profile for Duo and the infusion systems segment? - There is a positive outlook for both consumables and infusion systems, with installations of Duo underway [42][44] Question: How does the suspension of Baxter's no room pump sales affect the company? - While it may create some opportunities, the long-term view remains that all competitors will eventually return to the market [53] Question: What is the status of ongoing planning consolidation? - The move of infusion pumps to Costa Rica is complete, with other consolidations expected to be finalized within the next six to nine months [64] Question: Is the replacement cycle starting to contribute to revenue? - The replacement cycle is not yet significant, but discussions are beginning, with expectations for next year [71][72]